Shin Nippon Biomedical Laboratories ROA 2024

Mis teeb Shin Nippon Biomedical Laboratories?

Shin Nippon Biomedical Laboratories Ltd (SNBL) is a Japanese company that was founded in 1957. The company is headquartered in Tokyo, Japan. SNBL is an important player in the research and development industry, offering a wide range of services in the field of biomedical research. SNBL's business strategy is based on providing services to pharmaceutical companies and other medical institutions. The service portfolio includes both the development phase and the approval and post-marketing monitoring of drugs. SNBL offers a comprehensive service in this area, ranging from experimental planning to study implementation, report creation, and results analysis. The company has several geographical offices in Asia, Europe, and America to serve its customers worldwide. SNBL is divided into different divisions specializing in different areas of biomedical research. One important division is the Non-human Primates (NHP) research program. SNBL is able to provide a wide range of NHP species for research, ranging from rhesus monkeys to monkeys from China and Africa. These animals are used for research projects both for drug safety assessment and disease exploration. SNBL is also active in the field of genetic engineering, offering a wide range of services in this area. The company has several cell-based assay systems for drug development and experience in producing recombinant proteins for research. SNBL also offers analysis services for nucleic acids and proteins of all kinds and has extensive expertise in genotyping and gene expression analysis. Another pillar of SNBL's activities is toxicology and safety research. SNBL is a leading provider of toxicology studies, advising its clients on the design of animal safety assessment studies. The company also provides a wide range of non-GLP studies for toxicity evaluations. Additionally, SNBL is able to evaluate the results of toxicology studies and conduct risk analyses for specific products. SNBL also has its own drug development pipeline and has several products in development. One example is Nafamostat Mesilate, a drug being developed for the treatment of acute respiratory distress syndrome and acute pancreatitis. The company works closely with its clients to develop customized solutions for their specific research needs. SNBL's products and services make a significant contribution to the biomedical research industry and have worldwide impact on the healthcare of humans and animals. The company has a long history in the research industry and is recognized as a provider of services for drug development due to its expertise and experience. With its extensive services for biomedical research, SNBL will remain an important player in this field in the future. Shin Nippon Biomedical Laboratories ist eines der beliebtesten Unternehmen auf Eulerpool.com.